United Asset Strategies Inc. Boosts Position in Eli Lilly and Company (LLY)

United Asset Strategies Inc. raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 61.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 8,173 shares of the company’s stock after purchasing an additional 3,122 shares during the period. United Asset Strategies Inc.’s holdings in Eli Lilly and were worth $699,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Armor Investment Advisors LLC bought a new position in shares of Eli Lilly and in the third quarter worth about $200,000. Smith Moore & CO. bought a new position in shares of Eli Lilly and in the third quarter worth about $205,000. Cambridge Trust Co. boosted its stake in shares of Eli Lilly and by 37.3% in the third quarter. Cambridge Trust Co. now owns 7,369 shares of the company’s stock worth $631,000 after acquiring an additional 2,000 shares during the period. Rockland Trust Co. boosted its stake in Eli Lilly and by 4.5% during the third quarter. Rockland Trust Co. now owns 41,744 shares of the company’s stock valued at $3,571,000 after buying an additional 1,810 shares during the last quarter. Finally, American Century Companies Inc. boosted its stake in Eli Lilly and by 20.5% during the third quarter. American Century Companies Inc. now owns 2,242,866 shares of the company’s stock valued at $191,855,000 after buying an additional 381,299 shares during the last quarter. 76.42% of the stock is owned by institutional investors and hedge funds.

A number of brokerages recently commented on LLY. Credit Suisse Group reissued a “hold” rating on shares of Eli Lilly and in a research note on Wednesday. BMO Capital Markets set a $73.00 price target on Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday. Morgan Stanley increased their price target on Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 21st. Zacks Investment Research lowered Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Finally, Berenberg Bank restated a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a research report on Thursday, October 26th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $90.25.

Eli Lilly and Company (NYSE LLY) traded up $1.18 on Thursday, reaching $87.89. The company’s stock had a trading volume of 5,786,800 shares, compared to its average volume of 3,683,472. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The stock has a market cap of $95,475.95, a P/E ratio of 21.20, a P/E/G ratio of 1.77 and a beta of 0.35. Eli Lilly and Company has a one year low of $67.54 and a one year high of $89.09.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.02. The business had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.88 EPS. equities analysts anticipate that Eli Lilly and Company will post 4.21 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be given a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a yield of 2.56%. The ex-dividend date is Wednesday, February 14th. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio (DPR) is 98.58%.

In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 190,000 shares of the firm’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $82.53, for a total value of $15,680,700.00. Following the completion of the transaction, the insider now owns 123,682,287 shares of the company’s stock, valued at approximately $10,207,499,146.11. The disclosure for this sale can be found here. Insiders have sold a total of 641,088 shares of company stock worth $54,480,286 in the last ninety days. Insiders own 0.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Week Herald and is the sole property of of Week Herald. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://weekherald.com/2017/12/14/united-asset-strategies-inc-boosts-position-in-eli-lilly-and-company-lly.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply